Neurodegenerative diseases are increasing in number, given that the general global
population is becoming older. They manifest themselves through mechanisms that are not …

The aim of this international guideline on dementia was to present a peer‐reviewed
evidence‐based statement for the guidance of practice for clinical neurologists, geriatricians …

BackgroundCross-sectional studies support an association between depression and
inflammatory markers. However, little is known of their relationship in the context of …

Alzheimer's disease (AD) is the most common neurodegenerative disorder, affecting millions
of people worldwide. Apart from age, the major risk factor identified so far for the sporadic …

Drug repositioning or repurposing is the process of discovering leading-edge indications for
authorized or declined/abandoned molecules for use in different diseases. This approach …

Huntington's disease (HD) is an autosomal dominant genetic disorder caused by an
expansion of the CAG repeat in the first exon of Huntingtin's gene. The associated …

Alzheimer's disease (hereafter AD) is a progressive neurodegenerative disorder that affects
the central nervous system. There are multiple factors that cause AD, viz., accumulation of …

Statins have been reported to reduce the risk and be of benefit in the treatment of
Alzheimer's disease (AD). Individuals enrolling in the randomized controlled trial testing two …

Polymorphic genes associated with Alzheimer's disease (see) delineate a clearly defined
pathway related to cerebral and peripheral cholesterol and lipoprotein homoeostasis. They …

Alzheimer's disease (AD) is the most common form of dementia in industrialized nations. If
more effective therapies are not developed that either prevent AD or block progression of the …